5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions
LONDON, May 25, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP“) portfolio, demonstrating significant progress already made by the Company in 2023.
Small Pharma aims to protect its pipeline programs through a multi-layered IP strategy with four core areas of protection. These areas of protection include: Composition of Matter, covering novel drug substances; Medical Use, covering therapeutic compositions and medical uses thereof; Drug Product, covering pharmaceutical formulations; and Synthetic Route, covering the novel and efficient synthesis of high purity drug substance at scale.
Since the previous IP portfolio update on February 1, 2023, the Company has secured five new granted patents, with three more expected to be granted by May 31, 2023. Additionally, it has received five patent Notices of Allowance. The additional IP covers the four focused areas of protection and multiple markets, strengthening the Company’s international IP position.
The new patent grants and Notices of Allowance are summarized below.
Patent Protection |
Description | Market | Patent No. | Status |
Composition of Matter |
For certain deuterated homologues of certain tryptamine compounds | USA | 11,578,039 | Granted |
For certain deuterated homologues of certain tryptamine compounds | New Zealand |
788543 | Granted | |
For certain deuterated analogues of N,N, dimethyltryptamine (“DMT”) | GB | 2 592 822 | Grant expected after May 22, 2023 |
|
For a group of deuterated homologues of DMT | USA | 11,660,289 | Grant expected on May 30, 2023 |
|
For a group of deuterated homologues of DMT | Europe | 4 031 529 | Notice of Allowance |
|
Medical Use | Of certain deuterated analogues of DMT | GB | 2 586 940 | Grant expected after May 25, 2023 |
Medical use and therapeutic compositions of a group of deuterated homologues of DMT | Australia | 2021204158 | Notice of Allowance |
|
Medical use and therapeutic compositions of a group of deuterated homologues of DMT | New Zealand | 794833 | Notice of Allowance |
|
Therapeutic compositions of a group of deuterated homologues of DMT | Japan | 2022-574099 | Notice of Allowance |
|
Drug Product | Novel optimized injectable formulation of DMT based compounds | Australia | 2021334933 | Granted |
Therapeutic solid dosage forms of deuterated DMT analogues | GB | 2 595 776 | Granted | |
Synthetic Route | Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale | USA | 11,643,390 | Granted |
Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale | Canada | 3160337 | Notice of Allowance |
As of May 24, 2023, Small Pharma’s IP portfolio consists of 19 granted patents, with 97 allowed or pending. The protection covering each of the Company’s pipeline programs is outlined below.